Session C4
Room: Brookfield, Thursday 2.30-5.15

Valuing and evaluating regenerative medicine's healthcare potential
Chairs: Prof Andrew Webster, SATSU, University of York

- Professor Tony Pagliuca, clinical lead for Regenerative Medicine in the NHS Executive Clinical Reference Group for specialised commissioning.
    - *A summary of the scientific state of the art in the context of healthcare* –
- Geoff Banda/James Mittra
    - *Business models* –
- Aurelie Mahalatchimy /Joyce Tait
    - *Regulation and HTA* (i.e. NICE & NHSE) *policy*–
- Alex Faulkner
    - *Healthcare adoption and payment scenarios* -
- *Magda Papadaki,* Head of Manufacturing Innovation, Manager of the Medicines Manufacturing Industry Partnership (MMIP), Association of British Pharmaceutical Industries (ABPI) - innovation and industry perspective
- *Matthew Durdy*, Chief Business Officer, Cell & Gene Therapy Catapult, London – health economics perspective
- *Deborah Morrison ,* Senior Scientific Adviser, NICE Scientific Advice, Centre for Health Technology Evaluation, NICE - HTA/health system regulatory perspective

Regenerative medicine, consisting of cell therapies, gene therapy, tissue products and biomedical devices, promises to revolutionise medical treatment and is a political priority in UK and other governments' life science health and wealth policies. The field and its innovators face a number of challenges, especially a challenge to the prevailing centralised national modes of health technology assessment and models for reimbursing producers, in conditions of high scientific and clinical uncertainty, heightened by calls to increase the acceptability of 'real world evidence'. Alongside these challenges to evaluation policies and methodologies, the social sciences, notably Science & Technology Studies, have seen a recent turn toward a concern with 'valuation', and the microprocesses, discursive practices, and tools by which the social and economic worth of social goods is constructed and negotiated. This session will showcase recent findings and analysis from UK-focused ESRC qualitative research (REGenableMED: *"Regenerative medicine and its development and implementation: an analysis of emergent value systems and health service readiness"),* which is developing novel approaches to analysing disruptive innovation, including the construction of future business models and value chains in the context of the complex innovation and regulatory ecosystem. The findings will be submitted to detailed stakeholder debate, and act as a case study to bring into dialogue policy debate about valuing innovative medical technology, with academic perspectives on social processes of valuation practices, alongside the entrepreneurial challenges. Debate:"Society and healthcare system needs in order to benefit from regenerative medicine".